Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Immunocore Holdings (IMCR) Gross Profit (2023 - 2025)

Immunocore Holdings' Gross Profit history spans 3 years, with the latest figure at $101.8 million for Q4 2025.

  • For Q4 2025, Gross Profit rose 21.56% year-over-year to $101.8 million; the TTM value through Dec 2025 reached $394.9 million, up 28.44%, while the annual FY2025 figure was $394.9 million, 28.44% up from the prior year.
  • Gross Profit for Q4 2025 was $101.8 million at Immunocore Holdings, down from $103.2 million in the prior quarter.
  • Across five years, Gross Profit topped out at $103.2 million in Q3 2025 and bottomed at $54.4 million in Q1 2023.
  • The 3-year median for Gross Profit is $76.7 million (2024), against an average of $79.2 million.
  • The largest annual shift saw Gross Profit grew 19.67% in 2024 before it surged 32.44% in 2025.
  • A 3-year view of Gross Profit shows it stood at $70.0 million in 2023, then increased by 19.67% to $83.7 million in 2024, then grew by 21.56% to $101.8 million in 2025.
  • Per Business Quant, the three most recent readings for IMCR's Gross Profit are $101.8 million (Q4 2025), $103.2 million (Q3 2025), and $96.9 million (Q2 2025).